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the CC BY-NC-ND license (http://creaAbstract Prostate cancer (PCa) is the second most common cancer among men worldwide
and even ranks first in Europe. Although Asia is known as the region with the lowest PCa inci-
dence, it has been rising rapidly over the last 20 years mostly due to the introduction of
prostate-specific antigen (PSA) testing. Randomized PCa screening studies in Europe show a
mortality reduction in favor of PSA-based screening but coincide with high proportions of un-
necessary biopsies, overdiagnosis and subsequent overtreatment. Conclusive data on the value
of PSA-based screening and hence the balance between harms and benefits in Asia is still lack-
ing. Because of known racial variations, Asian countries should not directly apply the European
screening models. Like in the western world also in Asia, new predictive markers, tools and risk
stratification strategies hold great potential to improve the early detection of PCa and to
reduce the worldwide existing negative aspects of PSA-based PCa screening.
ª 2017 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Incidence of prostate cancer in Europe and
Asia
Prostate cancer (PCa) is the second most common malig-
nancy and the fifth leading cause of cancer death in men
worldwide [1]. However, the incidence differs by more than
25-fold among regions, with the highest in Australia/New
Zealand and the lowest in South-Central Asia [1] (Fig. 1).
This wide variation in incidence is strongly related to the
use of the prostate-specific antigen (PSA) test as aent of Urology, Erasmus
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tivecommons.org/licenses/by-nc-screening tool [2]. In most European countries such as
France, The Netherlands, and the Czech Republic, the PCa
incidence increased significantly in the early 1990s, soon
after the introduction of the PSA test, and is still increasing
[3,4]. The incidence in Asian countries like China and
Japan, began to increase after 1995. Although later than in
Europe because of the delayed use of the PSA test as a
screening tool, the increase of PCa incidence in Asian
countries is more pronounced in a comparable period [3]
(Fig. 2).
As said, the worldwide variation in the use of the PSA
test is probably the most important reason for the vari-
ability in PCa incidence. It is interesting to note that in the
early 1980s, when PSA was not yet used, a nearly 20-fold
PCa incidence difference already existed (USA 91.43 vs.
Japan 4.87, per 100,000) [5]. This could be explained by
factors like dietary differences (e.g., a high-fat diet in theon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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Figure 1 Prostate cancer incidence worldwide [1]. Adapted
with permission.
Prostate cancer screening in Europe and Asia 87western world), the prevalence of obesity, and genetic
factors [3]. A striking example is the significantly higher PCa
incidence in Japanese-American men than in native Japa-
nese men, suggesting that westernization through a high-
fat diet is strongly related to the risk of having PCa [6].
Furthermore, the PCa incidence in African-American men is
2e3 times higher than in White and Asian-American men in
the US, which indicates that gene and race also contribute
to PCa risk [7].
2. Screening trials in Europe and Asia
The European Randomized Study of Screening for Prostate
Cancer (ERSPC) is the largest randomized trial for PCa
screening and is still ongoing. It started in 1993 and includes
162,338 men, aged 55e69 years at time of randomization.
After 13 years of follow-up, the trial showed that PCa
mortality was reduced by 21% in favor of the screening arm
[8]. This finding is contrary to that of a large American
randomized trial, the so-called prostate arm of the Pros-
tate, Lung, Colorectal, and Ovarian Cancer Screening Trial
(PLCO). This trial, also initiated in 1993 and in which 76,685
men were randomized showed no difference in PCa mor-
tality between the screening and control arm with 13 years
of follow-up [9]. A recent publication on the basis of the
PLCO data showed a 90% PSA contamination rate in the
control arm which seriously questions the value of the re-
ported outcomes [10].
The Goteborg Randomized Prostate Cancer Screening
Trial is a European prospective, randomized trial that
started in 1995 and included 19,904 men, aged 50e64 yearsFigure 2 Prostate cancer incidence trend in Eat time of randomization. After 14 years of follow-up, it
showed that PCa mortality decreased by 44% in the
screening group as compared to the control group [11].
It is important to note that all three PCa screening trials
were based on Caucasian populations. Hence, their out-
comes cannot be directly translated to an Asian population.
The Japanese Prospective Cohort Study of Screening for
Prostate Cancer (JPSPC) is the only known prospective
controlled PCa screening study in Asia (Table 1). It started
in 2002 and ended in 2014. The aim of the study is to
compare the PCa mortality between the screening and
control cohort. This study comprises of 200,000 men in the
age range between 50 and 79 from Hokkaido, Gunma, Hir-
oshima and Nagasaki prefectures. A PSA 3 ng/mL in men
aged 50e64 years, a PSA 3.5 ng/mL in men aged 65e69
years and a PSA 4.0 ng/mL in men aged 70e79 years
triggered biopsy [12]. The compliance rate of PSA testing in
the Isesaki city screening cohort was about 75% over 5 years
and the contamination (PCa screening) in the Kiryu city
control cohort was low at 8% between 1992 and 2006 [13].
The contamination rate for the whole control cohort is
expected to be considerably low, due to the absence of
opportunistic PCa screening in Japan. The study outcome is
eagerly awaited to show whether PSA-based screening has
any potential in an Asian setting [14].
The Kanazawa population-based screening cohort study
is another large PCa screening study in Japan. A total of
32,769 men aged 55e69 years participated in the program
from 2000 to 2006. Contrary to the JPSPC study, the indi-
cation of biopsy varied among the different urologists
participating in this study. From 2000 to 2002, all men with
a PSA > 2.1 ng/mL were recommended to undergo the
secondary screening (consisting of a digital rectal exami-
nation (DRE) and transrectal ultrasonography (TRUS) ex-
amination) and to consult a urologist who would decide
whether or not to perform a systematic biopsy taking into
account the results of the DRE and TRUS [15]. From 2003
onwards, men with PSA values 2.1e10.0 ng/mL and a free
PSA/total PSA ratio (%fPSA) higher than 0.22, were not
referred for further screening. 4766 men (14.9%) required
secondary screening and 1041 men (3.2%) underwent pros-
tate biopsy. A total of 249 men (0.76%) were diagnosed with
PCa, of whom 231 (93.5%) were classified as clinically
localized cancer. Comparing the outcomes of this screening
study with those done among predominantly Caucasian men
it again highlights the considerable difference in PCaurope and Asia [3]. Adapt with permission.
Table 1 PCa screening trails in Asia.
Screening trial Country No. participants Age group
(years)
Follow-up time
(years)
Main conclusions
JPSPC [13] Japan 200,000 50e79 N/A N/A
Kanazawa [15] Japan 32,769 55e69 6 PCa incidence: 0.76%
Survival rate: 97.8%
The Korean Heart Study [17] South Korea 118,665 20 Mean 11.6 PCa mortality: 0.047%
Changchun [84] China 12,027 50 3 PCa incidence: 0.34%
Riyadh [19] Saudi Arabia 2100 50 1 PCa incidence: 2.5%
Dharan [85] Nepal 1521 50 1 PCa incidence: 0.73%
Ho Chi Minh city [86] Vietnam 408 50 1.5 PCa incidence: 2.5%
JPSPC, the Japanese prospective cohort study of screening for prostate cancer.
88 K. Zhang et al.incidence; 0.76% and 8.33% in this Japanese screening study
and the ERSPC respectively) [8]. The percentage of local-
ized tumors (T1,T2) in Japan was, however, remarkably
higher than in the ERSPC (93.5% vs. 78.2%) [16].
A South Korean screening study focused on the relation
between the PSA value and PCa mortality. It included
118,665 men from 1994 to 2004, and followed these men up
to 2011. The results showed a PCa death risk of 1.0%, 1.57%,
2.41%, 4.32% and 65.0% for baseline PSA values of <1.0,
1e2, 2e4, 4e10 and  10 ng/mL respectively after
adjusting for age, body mass index (BMI) and smoking status
[17]. By contrast, although having a longer follow-up, in a
subgroup of The Malmo Preventive Project which included
1167 men aged 60 years and who were followed up to age
85 years, the risk of dying of PCa at age 85 years was 0.9%,
2.7%, 11%, 17% and 30% for PSA levels 1.06, 1.50, 3.40, 5.17
and 14.8 ng/mL at age 60 respectively [18]. When
comparing similar PSA levels, European men seem to have a
higher risk of dying of PCa than Asian men.
In Saudi Arabia in West Asia, a small PCa screening study
was conducted between January e December 2008 to
explore the prevalence of PCa in a healthy cohort of men
and to assess the feasibility of a potential screening pro-
gram. The study included 2100 healthy men among whom
223 men had elevated PSA values (4 ng/mL) and 132 men
underwent prostate biopsy. A total of 52 men were diag-
nosed with PCa and nearly half of the cancers were already
locally advanced or metastatic [19].
Apart from the variance in incidence and mortality,
differences in treatment outcome were also observed
[20e22]. In an American study, for instance, of the 294,160
patients diagnosed with clinically localized PCa, 42.1% un-
derwent surgery, 34.5% underwent radiotherapy and 23.3%
underwent no treatment. The 10-year disease-specific
survival rate was highest among Asian men (94.7%), as
compared to White (93.5%), Hispanic (93.2%), and Black
men (91.8%) [20]. A Japanese study reported that
Japanese-American men had better outcomes following
hormonal therapy in terms of overall and PCa-specific sur-
vival as compared to Caucasian men [21]. All these data
suggest that PCa characteristics vary between races and
highlight the need for the development of a population-
specific guideline.
It must be noted, however, that due to considerable
differences in terms of the political system, the economicclimate and health policy in Asia, it will be difficult to
organize a large randomised controlled PCa screening trial
like the ERSPC study. It might therefore be an option to
apply statistical modeling and combine results of the
various Asian screening trials that are available. Whether
PSA-based screening can reduce PCa mortality in Asia is
currently still unknown.3. Benefits and harms of PSA-based screening
Obviously, PCa screening can lead to the early detection of
a tumor and subsequently in combination with adequate
treatment can avoid cancer progression and even metas-
tases. A British study calculated the lifetime risk of being
diagnosed with and dying from PCa by different races in
England between 2008 and 2010. It showed that the life-
time risks of being diagnosed with and dying of PCa were 1
in 8 and 1 in 24 respectively in White men. Lifetime risks of
being diagnosed with and dying of PCa in Asian men were 1
in 13 and 1 in 44 respectively [23]. It should be noted that
the risk of diagnosis in White men is 1.6 times higher than in
Asian men, which is actually very close to the ratio of death
risk between the two races, being 1.8. Hence, if the risk of
diagnosis and death rise or decline equally, the harm-to-
benefit ratio of screening will remain stable [24].
The Malmo Preventive Project study indicated that
starting PSA-based screening at age 45e49 years can avoid a
considerable number of men from suffering metastatic PCa
compared to starting screening at age 51e55 years [25]. On
the basis of this observation several guidelines currently
suggest that men should start PCa screening at an early age.
For instance, the European Association of Urology (EAU)
recommended baseline PSA testing of men in their 40s to
predict the future risk of PCa [26]. The Memorial Sloan
Kettering Cancer Center (MSKCC) recommended to start
screening at age 45 years [27]. In addition, since young men
have a lower incidence of benign prostatic hyperplasia (BPH)
that also influences the serum PSA value, an elevated PSA
level at young age better reflects the presence of PCa [28].
While these data show the potential of PSA-based risk
stratification, it is crucial to acknowledge that a purely
PSA-based screening algorithm also results in large numbers
of unnecessary biopsies and the detection of potentially
indolent PCa. This so-called overdiagnosis often leads to
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with an elevated PSA value (3 ng/mL) had a benign biopsy
result, and 72.2% of the PCa detected in the screening arm
had low-risk disease (Gleason score 6) [30]. In ERSPC Rot-
terdam, as many as 58.1% men with low-risk PCa underwent
aggressive treatment [31].
In another smaller Korean population screening study,
3943 men 55 years of age were included. It showed that
among 719 men with PSA values 3 ng/mL 71.6% of the
biopsies showed a benign result and were unnecessary at
that point in time. In addition, 53.9% of the PCa detected
had a Gleason score of 2e6 [32]. In a relatively small two-
country (Japan, China) PCa screening study of 5778 men,
a PSA value of 4.1 ng/mL was used as cut-off for prostate
biopsy, 73.4% of the biopsies had a benign result [33].
In 2012, having reviewed all the available data on
prostate cancer screening, the United States Preventive
Services Task Force (USPSTF) recommended against PSA-
based screening for PCa [34]. Recently the first studies
reported on the consequences of this recommendation. In
general there is a decreases in PSA testing rates [35e49].
However, while screening rates in men over 75 continued to
decline, a decline was also noted in younger men for whom
PSA screening has demonstrated benefit. In addition, men
at high risk for developing PCa also received less screening
[38,46,50]. However, it is still unclear whether unnecessary
testing and over diagnosis has actually decreased [51].
In conclusion, it is unclear whether PSA based screening
results in a PCa mortality reduction in Asian countries.
Results of the JPSPC study are awaited and can hopefully
give more insight. There is however reason to assume that
the harm-to-benefit ratio of PSA-based screening in Asian
men is comparable to that in the western world. This im-
plies that also in Asia, optimization of PCa screening algo-
rithms has to be based on introducing new biomarkers, risk
prediction tools and individual risk based screening
strategies.
4. Application of new markers and tools in
Europe and Asia
4.1. PSA subforms
PSA circulates in the serum in two forms, the complex form
(PSA binded to a1-antichymotrypsin) and the free form
known as free PSA (fPSA). proPSA is a molecular subform of
fPSA and has three known forms: [-2], [-4], and [-5/-7]
proPSA, in which [-2]proPSA (p2PSA) is the most stable one
[52,53].
The so-called Prostate Health Index (PHI) combines
three PSA-based biomarkers using the following formula:
(p2PSA/fPSA)  PSA1/2. It was developed by Beckman
Coulter, Inc in cooperation with the NCI Early Detection
Research Network and then approved by U.S. Food and Drug
Administration (FDA) in 2012 [54].
In a multicenter European study, a total of 883 men with
elevated PSA values and/or suspicious DRE results under-
went prostate biopsy. Total PSA (tPSA), fPSA, p2PSA levels
were measured upfront and the %fPSA and PHI were
calculated. On the basis of biopsy outcome (PCa detected
yes or no), PHI showed the best discrimination of PCa withareas under the curve (AUC) of 0.68 as compared to tPSA
(AUC 0.51) and %fPSA (AUC 0.64) [55]. In another five-
center European study of 646 biopsied men with PSA
levels 2e10 ng/mL, PHI also showed better performance
than tPSA, fPSA, %fPSA or p2PSA in predicting PCa with
Gleason 7 (AUC’s of 0.65 vs. 0.54, 0.56, 0.59, 0.54,
respectively) [56].
A study from Hong Kong included 230 biopsied men with
PSA levels 4e10 ng/mL and confirmed that PHI achieved the
highest predictive value for predicting PCa (AUC 0.781) as
compared to %fPSA (AUC 0.654) and PSA (AUC 0.547) [57]. In
another Chinese study of 636 biopsied men from Shanghai,
the AUC of PHI for predicting PCa was as high as 0.88 [58].
These data, although being small in size suggest that PHI
has more discriminatory capability (higher AUC) in Asian
populations as compared to European populations. In
addition, although the mean and median PSA values of men
were similar in the Asian and European studies (mean PSA
6.29 ng/mL (range 4.0e9.5) vs. median PSA 6.39 ng/mL
(range 0.5e19.9)) [55,57], the cancer detection rate
differed remarkably (9.13% vs. 41.3%), suggesting that
these European and Asian studies might not be comparable.
This difference in cancer detection is further confirmed
by the fact that when comparing the Chinese study [58] to
the European study [55], it was shown that the positive
biopsy rate was comparable: 43.1% vs. 41.3% respectively.
However, the median PSA value of cancer cases was
significantly different (31.78 vs. 9.36 ng/mL).
The available data on PHI in Asian men suggest that PHI
has a good, perhaps even better discriminative capability
than PSA. It is, however, important to realize that the Asian
and western study populations are not directly comparable
and more data are needed to assess the value of PHI in
predicting biopsy outcome in Asian men.4.2. Genetic markers
Next to PSA subforms, gene-based tests have been devel-
oped with the aim to improve the prediction biopsy
outcome. Well-known tests are the prostate cancer gene 3
(PCA3) and the transmembrane protease, serine 2
(TMPRSS2):v-ets erythroblastosis virus E26 oncogene homo-
log (ERG) tests [59]. Since these tests are urine-based, they
are noninvasive and as such convenient in daily clinic
practice [60]. The clinical benefits of PCA3 and
TMPRSS2:ERG will have to be assessed further in Asian men
as well as its cost-effectiveness. In the UK it has been shown
that in an NHS-setting PCA3 was not cost-effective, but this
may be different for an Asian population of change in the
future due to technological improvements [61].
PCA3 is a non-coding RNA that was found to be highly
overexpressed in PCa cells as compared to normal prostate
tissue. In 2012, PCA3 was approved by the FDA for PCa
detection [62,63].
A multicenter study, with the aim to test the added
value of PCA3 in pre-biopsy risk stratification was con-
ducted in Europe and North America and included 809 men
[64]. The median PSA level of the study cohort was
6.3 ng/ml and PCa was detected in 319 men (39.1%). PCA3
showed a higher discriminative capability than PSA (AUC
0.679 vs. 0.527) [64].
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tween 2009 and 2011 is the only large Asian study that
assessed the value of PCA3. It comprised of 647 men with
PSA values considered to be elevated (median PSA
7.6 ng/ml) and/or abnormal DRE. All men underwent
prostate biopsy and 264 patients (41.7%) were diagnosed
with PCa. PCA3 significantly outperformed total PSA in
predicting biopsy outcome; with AUC’s of 0.748 and 0.583
respectively [65].
TMPRSS2:ERG is a fusion gene that is present in
approximately 50% of PCa cases [62]. In a European study
including 443 men, TMPRSS2:ERG (cut-off 10 copies
mRNA) showed a specificity of 93.2% and a sensitivity of
24.3% for clinically significant PCa defined as clinical
stage  T2, Gleason score 7, PSA density >0.15, and >33%
positive cores. In contrast, when using a PCA3 cut-off of
35, a specificity of 58.3% and a sensitivity of 68.4% were
found [66]. TMPRSS2:ERG showed lower AUC’s as compared
to PCA3 and PSA (AUC’s 0.59 vs. 0.72 vs. 0.67) due to its low
sensitivity [66].
In a Japanese study of 102 men, TMPRSS2:ERG (cut-off
20 copies mRNA) also showed a very high specificity of
93.5%, and a low sensitivity of 27.5% for PCa. The AUC of
TMPRSS2:ERG, PCA3 and PSA were comparable with the
European study mentioned above (0.604, 0.824 and 0.691,
respectively). It should be noted that the cut-off of
TMPRSS2:ERG differed between the two studies [62].
Because of the low sensitivity of TMPRSS2:ERG, combining
it with other markers, e.g., TMPRSS2:ERG with PSA or
TMPRSS2:ERG with PSA and PCA3, is likely to improve test
performance [67]. The European study mentioned above
showed that TMPRSS2:ERG (cut-off 10) plus PCA3 (cut-off
25) increased sensitivity from 24.3% to 88.1%, while a
decrease in specificity from 93.2% to 49.6% was seen [66].
Based on the existing data, PCA3 and TMPRSS2:ERG seem
to have similar performance between European and Asian
populations. However, and this applies for the European,
but certainly also for the Asian setting, due to limited
availability and unknown clinical effectiveness, PSA remains
the most widely used marker for the detection of PCa.
4.3. Multiparametric MRI (mpMRI)
In Europe MRI has been used in the diagnosis of PCa since
the 1980s. At first, only T1-weighted (T1W) and T2-
weighted (T2W) pulse sequences were available, limiting
the ability to distinguish benign prostate nodes from PCa
[68]. mpMRI is a new technique combining anatomic T2W
with functional and physiological assessments, including
diffusion-weighted imaging (DWI) with apparent-diffusion
coefficient (ADC) maps and dynamic contrast-enhanced
(DCE) MRI. MpMRI not only improves detection of PCa, but
in addition, as is shown in several studies can differentiate
between indolent and clinically significant PCa [68], which
is crucial in avoiding overdiagnosis of PCa.
A five-point scale system which is known as the Prostate
Imaging-Reporting and Data System (PI-RADS) has been
developed to classify suspicious lesions on prostate mpMRI
with points ranging from 1 (no suspicion) to 5 (high suspi-
cion) [69]. In 2015, the PI-RADS system has been updated(PI-RADS 2.0) and extensive information was added on how
to acquire, interpret and report mpMRI of the prostate [70].
In addition to having the availability of anatomical/struc-
tural and functional imaging of the prostate, advances in
technology have led to the development of the so-called
MRI-targeted prostate biopsy. This technique comprises of
MRI in-bore-guided biopsy, MRI visual estimation-guided
biopsy and MRI/TRUS fusion-guided biopsy [71,72].
In a European systematic review, 1926menwith a positive
MRI from 16 studies were included with the aim to compare
MRI-targeted biopsy (including in-bore, visual and fusion-
guided biopsy) with transrectal ultrasound (TRUS)-targeted
biopsy in detecting PCa and significant PCa [73]. Analyses
showed that both modalities had similar performance in
overall PCa detection (sensitivity: MRI-targeted biopsy 85%,
TRUS-targeted biopsy 81%), but MRI-targeted biopsy had
remarkably higher sensitivity in significant PCa detection
(91% vs. 76%) and lower sensitivity in insignificant PCa
detection (44% vs. 83%). In the subgroup of men with an
initial biopsy, the two approaches had similar results in
overall PCa detection and a small difference in significant
PCa detection. However, the differences were most obvious
in men with a previous negative biopsy, either on overall PCa
detection (sensitivity: 88% vs. 54%) or significant PCa
detection (sensitivity: 87% vs. 56%) [73]. On the basis of the
available data, the EAU recommends mpMRI and MRI-
targeted biopsy in men with a previous negative biopsy [26].
Next to the European review, which mostly included
European and US based studies (two Korean small-sample
studies were also included), a Japanese study evaluated
the value of mpMRI in the detection PCa and significant PCa
in 288 men [74]. In this study, all men underwent a mpMRI
scan and a 14-core systematic biopsy. In addition, 2 MRI-
targeted biopsy cores were added for each suspicious or
equivocal lesions seen on mpMRI. Although PI-RADS system
was not yet available when the biopsies were taken, in
retrospect a single experienced uroradiologist reviewed all
MRI lesions according to the PI-RADS scoring system 2.0. It
showed that the PI-RADS score was a strong predictor for
the presence of PCa as compared to PSA and TRUS outcome
(AUC 0.835 vs. 0.622 and 0.543 respectively) [74].
In a Korean study of 76 men with a PSA level <10 ng/mL,
MRI-targeted biopsy showed a remarkable higher significant
PCa detection rate than TRUS-targeted biopsy (74.1% vs.
35.1%). In addition, the positive prostate biopsy rate per
biopsy core was 46.6% and 8.4% for MRI- and TRUS-targeted
biopsy respectively. This finding translates into a poten-
tially considerable reduction of unnecessary biopsies, bi-
opsy cores, as well as patients’ harm and costs [75].
Although the available Asian data on mpMRI and MRI-
targeted biopsy are currently limited, both in Asia and
Europe mpMRI holds great potential in improving the
selective-detection of clinically significant PCa and as such
reduce unnecessary biopsies and overdiagnosis. At present
time MRI-targeted biopsy is only available in a few Asian
centers and is not (yet) included in the guidelines of most
Asian Urological Associations. It is likely that for MRI
becoming more widespread available, visual (cognitive)
MRI-targeted biopsy holds the most potential in Asia, due to
costs and the relatively shorter learning curve.
Figure 3 Screenshots of the European Randomized Study of Screening for Prostate Cancer risk calculator (app).
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Crucial before deciding on a prostate biopsy, or even an
mpMRI is a proper risk stratification with the main goal to
avoid unnecessary interventions. In the three large PSA-
based screening trials PLCO, ERSPC and the Goteborg
screening trial, as well as in most Asian screening trials,
every man within a certain age range and surpassing a pre-
defined PSA cut-off value was biopsied resulting in large
numbers of unnecessary biopsies and the detection and
active treatment of many indolent tumors. An individual
multivariate risk-based screening strategy is based on the
concept of calculating a man’s personal risk using more
relevant pre-biopsy information coming from multiple
sources and subsequently apply a certain PCa risk value as a
threshold for prostate biopsy or subsequent screening [76].
There are a few well-known risk calculators based on
western populations, such as the Prostataclass model, the
Finne model, the Karakiewcz model, and the Prostate
Cancer Prevention Trial (PCPT) model [77e80].
Furthermore, an often-used, externally validated risk
calculator with good performance is the so-called ERSPCFigure 4 Screenshots of the Seoul National Universrisk calculator. This risk calculator is developed on the
Dutch data of the ERSPC trial, comprising of 19,970 men
repeatedly screened and biopsied. The risk calculator
consists of six different logistic regression models, each
requiring different pre-biopsy information ranging from
information available for lay men to information that re-
quires a visit to the urologist. The calculator is easily
accessible through the internet (www.prostatecancer-
riskcalculator.com) or through a smartphone-app (App:
Rotterdam Prostate Cancer Risk Calculator, Fig. 3). The risk
factors included in the various prediction models are age,
family history, IPSS score, PSA, ultrasound-assessed pros-
tate volume, DRE results, TRUS outcome, and previous bi-
opsy status [81]. The development study of risk calculator
step number 3 which predicts initial biopsy outcome
reached an AUC of 0.77 as compared to 0.64 for PSA alone
when predicting overall PCa [81] (Fig. 4).
Retrospective analyses of 1850 men biopsied in ERSPC
Rotterdam at initial screening, comparing a purely PSA-
based strategy (PSA 3 ng/mL) with a risk-based strategy
combining the PSA 3.0 ng/mL threshold with an individ-
ually calculated risk 12.5%, showed that 33% of biopsiesity prostate cancer calculator (Version 1.1, app).
92 K. Zhang et al.could be avoided. Although 14% of PCa would potentially be
missed with the risk-based strategy, 70% of these missed
cancers were classified as potentially indolent. At repeat
screening 4 years later, a similar strategy would result in
37% fewer biopsies while missing 16% of PCa diagnosis of
which 81% could be classified as potentially indolent. As a
comparison, applying a higher PSA threshold for biopsy
(4.0 ng/mL) could avoid similar numbers of unnecessary
biopsies, but would miss larger numbers of potentially
aggressive PCa’s (12% vs. 10% at initial screening, 50% vs.
15% at repeat screening) [81].
In Asia, the Seoul National University Prostate Cancer
Risk Calculator (SNUPC-RC) was developed. The risk
calculator is based on data from 3482 Korean men who were
all biopsied. In a validation cohort of 1112 Korean men, the
SNUPC-RC showed a high predictive value with an AUC of
0.811, the AUC of the ERSPC risk calculator validated in the
same Korean population was 0.768 [82]. When applying the
30%-threshold of the SNUPC-RC instead of a PSA level of
>4 ng/mL for biopsy, 21.5% of biopsies would be avoided
and only 1.4% of the PCa diagnoses would be missed [82].
When comparing the two risk calculators, it is notable
that the ERSPC risk calculator was developed on 6-core
biopsy scheme while the SNUPC-RC was based on a 12-
core biopsy scheme [82]. Furthermore, Korean men have a
different distribution of PSA levels than the European
population [83]. External validation studies confirm the
existence of racial variations and highlights that caution
should be paid to using risk calculator models outside their
region of origin, predominantly when proper validation
studies have not been conducted.
It must however be noted that as compared to a purely
PSA based strategy a risk based strategy is always better in
avoiding unnecessary biopsies and reducing potential
overdiagnosis, both in Europe and Asia.
5. The future of PCa screening
Since the incidence and tumor characteristics differ be-
tween European and Asian populations, it is crucial to
acknowledge that European-based screening outcomes are
not directly transferrable to an Asian setting. Similar con-
cerns, e.g., unnecessary testing and overdiagnosis exist and
like in the western world PSA-based population screening is
not recommended (yet).
Risk stratification has proven to be of aid in identifying
men at low risk of harboring aggressive disease and can as
such reduce unnecessary testing and overdiagnosis. Hence,
Asian countries need to develop or adapt western-based
risk stratification strategies using region-specific data.
mpMRI-guided biopsy holds great potential to replace
conventional systematic TRUS-guided biopsy. It can provide
direct visualization of suspicious lesions and improve diag-
nostic accuracy for significant PCa, especially in men with a
previous negative biopsy. As a new technique, however,
performance and cost-effectiveness needs validation in
Asian countries which is currently hampered by the avail-
ability of data.
PCa screening in most Asian countries is still in its in-
fancy, with the priority of assessing the effect on disease
specific mortality. This is contrary to most Europeancountries, where the focus now lies in reducing over-
diagnosis and overtreatment. Further research on PCa
screening in Asia should however be based on the European
experiences to avoid making the same mistakes. The con-
ventional model “PSA screening-biopsy-active treatment”
should not be duplicated. Instead, multivariate risk pre-
diction, tailored to the Asian setting, followed by imaging in
those considered at high risk for a potentially life threat-
ening PC is advised, preferably in a controlled setting of a
governmental regulated screening program.Conflicts of interest
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